Diffusion- weighted MRI and Ga68-DOTATOC PET for early monitoring of response to intra-arterial Y90/Lu177-DOTATOC therapy in patients with neuroendocrine liver metastases

被引：0
|
作者：
Giesel, Frederik [1 ]
Wulfert, Sarah [1 ]
Kuder, Tristan [2 ]
Schwartz, Lawrence [3 ]
Kauczor, Hans-Ulrich [4 ]
Haberkorn, Uwe [1 ]
Kratochwil, Clemens [1 ]
机构：
[1] Univ Hosp Heidelberg, Nucl Med, Heidelberg, Germany
[2] German Canc Res Ctr, Phys Med, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Radiol, Heidelberg, Germany
[4] Columbia Univ, Radiol, New York, NY USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1216
引用
收藏
页数：2
相关论文
共 23 条
  • [1] Diffusion-weighted MRI and (68)Ga-DOTATOC PET for early monitoring of response to intraarterial(90)Y-/(177)Lu-DOTATOC therapy in patients with neuroendocrine liver metastases
    Giesel, F.
    Wulfert, S.
    Kuder, T.
    Kauczor, H.
    Schwartz, L.
    Haberkorn, U.
    Kratochwil, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S289 - S289
  • [2] 68Ga DOTATOC PET/CT for treatment response of Peptide Receptor Radionuclide Therapy using 177Lu and 90Y-DOTATOC
    Finocchiaro, D.
    Grassi, E.
    Fioroni, F.
    Castellani, G.
    Lanconelli, N.
    Versari, A.
    Filice, A.
    Iori, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S288 - S288
  • [3] Impact of Ga68-DOTATOC PET/MRI on Therapy Management in Patients with Neuroendocrine Neoplasia (NEN) - Preliminary Results
    Radojewski, P.
    Nagel, S.
    Fehrenbach, U.
    Jann, H.
    Rogasch, J.
    Mogl, M.
    Roderburg, C.
    Goretzki, P.
    Makowski, M.
    Schatka, I
    Furth, C.
    Amthauer, H.
    NEUROENDOCRINOLOGY, 2020, 110 : 271 - 271
  • [4] Radiopeptide therapy with Y-90 or Lu-177 DOTATOC: Is treatment response predictable by pretherapeutic uptake of Ga-68 DOTATOC?
    Oeksuez, Mehmet
    Pfannenberg, Christina
    Bares, Roland
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [5] Multimodal Imaging for Early Functional Response Assessment of 90Y-/177Lu-DOTATOC Peptide Receptor Targeted Radiotherapy with DW-MRI and 68Ga-DOTATOC-PET/CT
    Wulfert, Sarah
    Kratochwil, Clemens
    Choyke, Peter L.
    Afshar-Oromieh, Ali
    Mier, Walter
    Kauczor, Hans-Ulrich
    Schenk, Jens-Peter
    Haberkorn, Uwe
    Giesel, Frederik L.
    MOLECULAR IMAGING AND BIOLOGY, 2014, 16 (04) : 586 - 594
  • [6] Multimodal Imaging for Early Functional Response Assessment of 90Y-/177Lu-DOTATOC Peptide Receptor Targeted Radiotherapy with DW-MRI and 68Ga-DOTATOC-PET/CT
    Sarah Wulfert
    Clemens Kratochwil
    Peter L. Choyke
    Ali Afshar-Oromieh
    Walter Mier
    Hans-Ulrich Kauczor
    Jens-Peter Schenk
    Uwe Haberkorn
    Frederik L. Giesel
    Molecular Imaging and Biology, 2014, 16 : 586 - 594
  • [7] Intra-Arterial Peptide Receptor Radionuclide Therapy Using Y-90 DOTATOC for Hepatic Metastases of Gastroenteropancreatic Neuroendocrine Tumors
    Heath, Courtney Lawhn
    Fidelman, Nicholas
    Bergsland, Emily
    Hope, Thomas
    PANCREAS, 2020, 49 (03) : 474 - 475
  • [8] Peptide receptor radionuclide therapy with Y-90 DOTATOC and Lu-177 DOTATATE in patients with progressive meningioma and prognostic value of pretherapeutic Ga-68 DOTATOC/-TATE PET/CT
    Ilhan, Harun
    Seystahl, Katharina
    Veit, Stoecklein
    Schueller, Ulrich
    Rushing, Elisabeth
    Nicolas, Guillaume
    Schaefer, Niklaus
    Pangalu, Athina
    Lehner, Sebastian
    Bartenstein, Peter
    Michael, Weller
    Tonn, Joerg
    Sommerauer, Michael
    Albert, Nathalie
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [9] Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC
    Cieciera, Matthaeus
    Kratochwil, Clemens
    Moltz, Jan
    Kauczor, Hans-Ulrich
    Holland-Letz, Tim
    Choyke, Peter
    Mier, Walter
    Haberkorn, Uwe
    Giesel, Frederik L.
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2016, 22 (03) : 201 - 206
  • [10] Subacute and Long-Term Hepatotoxicity Risk after 90Y-OR 177LU-DOTATOC Therapy - Is Hepatic Tumour Burden on 68Ga-DOTATOC PET/CT Predictive of Liver Dysfunction?
    Chirindel, A.
    Anongpornjossakul, Y.
    Wild, D.
    Nicolas, G.
    NEUROENDOCRINOLOGY, 2019, 108 : 204 - 204
123